Federal Circuit Vacates Summary Judgment of Non-Enablement Where the Only Alleged Non-Enabled Systems Did Not Practice the Claims

Jun 1, 2020

Reading Time : 2 min

In 2012, McRO, Inc., d/b/a Planet Blue (McRO) asserted U.S. Patent No. 6,611,278 (the “’278 Patent”) against defendant Bandai Namco Games Am. Inc. and over a dozen other video game developers (the “Developers”) in the District Court for the Central District of California. The ’278 Patent is directed to animating lip synchronization and facial expressions of animated characters three-dimensionally via a computer. The Developers produce and sell videogames with software that models facial animations in video game characters.

Previously, animators used “morph weight sets”—a set of values that, when applied, alter the animated subject’s default appearance so that they appear to speak a specific sound (e.g. “oo”)—and manually set the weight of each frame of a video game character’s mouth to properly depict them speaking. McRO patented a method to automate this process and generate character animations. Relevant to this appeal, McRO claimed a method of “obtaining a first set of rules that defines a morph weight set stream as a function of phoneme sequence and times associated with said phoneme sequence,” where a “phoneme” is a distinct unit of sound.

In a prior case, the district court determined that the asserted method claims of the ’278 Patent were invalid under 35 U.S.C. § 101 because they were directed to patent ineligible abstract subject matter. The Federal Circuit reversed that decision and remanded the case to the district court. On remand, the district court again found the claims invalid, this time granting the Developers’ motion for summary judgment of non-enablement. The district court also granted summary judgment of non-infringement. Specific to invalidity, the Developers relied on two animation techniques—bones animation and the BALDI system—as examples of systems not enabled by the specification of the ’278 Patent. The district court agreed that a person of skill in the art would be unable to practice the full scope of claim 1 because those techniques were not enabled. McRO appealed.

Enablement is a statutory requirement contained in 35 U.S.C. § 112. In short, a patentee must describe how to make and use the full scope of the invention without undue experimentation. Courts assess whether undue experimentation exists by utilizing the factors described in In re Wands. 858 F.2d 731 (Fed. Cir. 1988). Critically, however, § 112 requires enablement of only what is claimed, and is analyzed after the precise scope of the claimed invention is defined. A Wands analysis involves a concrete identification of embodiment(s) that are not enabled—particular products or processes that fall within the claim—so that breadth is shown concretely and not as an abstract possibility.

On appeal, the Developers argued that the bones animation and the BALDI system were not enabled. The Federal Circuit, however, determined that those animation techniques did not practice the claims. And because the bones animation and the BALDI system were the only examples identified by the Developers as not enabled, the court’s non-infringement determination left the Developers without a single specific example of a system that was both not enabled and practiced the claim. Without the support of a specifically covered technique, the Federal Circuit held that the district court’s non-enablement determination could no longer stand—it was too abstract and conclusory to support summary judgment of non-enablement.

Practice tip: When attempting to show that a patent does not enable the full scope of the claims, patent challengers should identify specific examples of non-enabled products or processes that practice the claims, and try to avoid relying solely on accused products or processes for which infringement may also be contested.

McRO, Inc. v. Bandai Namco Games Am., No. 19-1557 (Fed. Cir. May 20, 2020) (J. Taranto, Reyna, Mayer)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.